XXXX : is it already possible?

@entity1 @entity8168 @entity309 @entity24602
PURPOSE OF REVIEW: To give an overview of recently published articles covering drug-free remission in @entity309 ( @entity309 ). RECENT FINDINGS: Recent studies covering drug-free remission showed differences in numbers studied, remission definition, disease duration and medication used. @entity8168 was reported in 9-29%. Only two out of four studies reported on @entity1 who restarted medication due to a disease flare or loss of remission, which occurred in 45-46%. In the BeSt study, remission or low disease activity was achieved again after retreatment within 6 months in 96%. In the Finnish Early @entity309 study, none of the @entity1 achieved remission after retreatment; their mean Disease Activity Score (DAS28) was 3.68. Joint damage progression was not higher in @entity1 who restarted medication when compared to @entity1 in sustained drug-free remission or @entity1 with continued treatment. Anticitrullinated protein antibody, @entity309 factor or @entity24602 and short symptom duration were independent predictors of successful drug-free remission in more than one cohort. SUMMARY: @entity8168 can be achieved and sustained in a small group of @entity309 @entity1 . In early @entity309 , retreatment is successful in the majority of @entity1 . Disease flare after cessation of medication does not seem to increase joint damage progression. Sustained drug-free remission is predicted by autoantibody and @entity24602 and short disease duration before treatment initiation.
